IRLAB Therapeutics Toekomstige groei

Future criteriumcontroles 2/6

IRLAB Therapeutics zal naar verwachting groeien in winst en omzet met respectievelijk 19.4% en 28.6% per jaar. De winst per aandeel zal naar verwachting groeien met 19.3% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -22.1% zijn.

Belangrijke informatie

19.4%

Groei van de winst

19.3%

Groei van de winst per aandeel

Pharmaceuticals winstgroei	69.5%
Inkomstengroei	28.6%
Toekomstig rendement op eigen vermogen	-22.1%
Dekking van analisten	Low
Laatst bijgewerkt	02 Nov 2024

Recente toekomstige groei-updates

Recent updates

We Think IRLAB Therapeutics (STO:IRLAB A) Needs To Drive Business Growth Carefully

Mar 18

IRLAB Therapeutics (STO:IRLAB A) Is In A Good Position To Deliver On Growth Plans

Dec 01

We Like IRLAB Therapeutics' (STO:IRLAB A) Earnings For More Than Just Statutory Profit

May 19

We're Interested To See How IRLAB Therapeutics (STO:IRLAB A) Uses Its Cash Hoard To Grow

Sep 11

We're Interested To See How IRLAB Therapeutics (STO:IRLAB A) Uses Its Cash Hoard To Grow

Apr 30

What Is The Ownership Structure Like For IRLAB Therapeutics AB (publ) (STO:IRLAB A)?

Mar 19

We Think IRLAB Therapeutics (STO:IRLAB A) Can Afford To Drive Business Growth

Jan 25

Our View On IRLAB Therapeutics' (STO:IRLAB A) CEO Pay

Dec 21

What Is The Ownership Structure Like For IRLAB Therapeutics AB (publ) (STO:IRLAB A)?

Nov 25

Winst- en omzetgroeiprognoses

OM:IRLAB A - Toekomstschattingen van analisten en financiële gegevens uit het verleden (SEK Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	89	-116	-116	-116	1
12/31/2025	219	-12	159	159	2
12/31/2024	123	-87	-17	-17	3
9/30/2024	63	-113	-77	-77	N/A
6/30/2024	42	-119	-109	-109	N/A
3/31/2024	6	-157	-162	-162	N/A
12/31/2023	6	-178	-165	-165	N/A
9/30/2023	19	-176	-169	-169	N/A
6/30/2023	36	-162	-163	-160	N/A
3/31/2023	52	-144	-155	-151	N/A
12/31/2022	61	-113	-146	-143	N/A
9/30/2022	61	-103	-136	-133	N/A
6/30/2022	240	42	96	98	N/A
3/31/2022	217	43	117	118	N/A
12/31/2021	208	52	128	129	N/A
9/30/2021	196	55	140	141	N/A
6/30/2021	0	-93	-93	-92	N/A
3/31/2021	N/A	-93	-88	-87	N/A
12/31/2020	0	-92	-90	-89	N/A
9/30/2020	0	-99	-99	-99	N/A
6/30/2020	0	-93	-93	-92	N/A
3/31/2020	1	-98	-98	-98	N/A
12/31/2019	0	-96	-91	-91	N/A
9/30/2019	1	-88	-83	-83	N/A
6/30/2019	1	-83	-78	-78	N/A
3/31/2019	0	-76	-75	-75	N/A
12/31/2018	0	-74	-72	-71	N/A
9/30/2018	0	-68	-76	-75	N/A
6/30/2018	0	-73	N/A	-67	N/A
3/31/2018	0	-60	N/A	-58	N/A
12/31/2017	0	-56	N/A	-58	N/A
9/30/2017	0	-58	N/A	-48	N/A
6/30/2017	0	-48	N/A	-45	N/A
3/31/2017	3	-44	N/A	-45	N/A
12/31/2016	3	-43	N/A	-41	N/A
12/31/2015	3	-12	N/A	-28	N/A
12/31/2014	3	3	N/A	-11	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat IRLAB A de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat IRLAB A de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat IRLAB A de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van IRLAB A ( 28.6% per jaar) zal naar verwachting sneller groeien dan de markt Swedish ( 0.02% per jaar).

Hoge groei-inkomsten: De omzet van IRLAB A ( 28.6% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Er wordt voorspeld dat IRLAB A binnen 3 jaar verliesgevend zal zijn.

IRLAB Therapeutics Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target decreased by 7.1% to kr56.63

Price target increased by 8.0% to kr60.95

Consensus revenue estimates increase by 178%

Consensus revenue estimates increase by 88%

Price target increased by 83% to kr59.05

Consensus forecasts updated

Recent updates

New minor risk - Profitability

IRLAB Therapeutics AB (publ) to Report Q2, 2025 Results on Jul 09, 2025

Is IRLAB Therapeutics (STO:IRLAB A) Using Debt Sensibly?

IRLAB Therapeutics AB Receives Milestone Payment of USD 2.5 Million in Conjunction with First Dosing in A Phase I Study with IRL757 in Healthy Adults

IRLAB Therapeutics AB Announces Positive Data from the First Part of Phase I Study with the Drug Candidate IRL 757

IRLAB Therapeutics AB (publ) Granted Additional Patent for Its Drug Candidate Pirepemat Expanding the Patent Protection in the US

New minor risk - Profitability

IRLAB Therapeutics AB Announces Phase IIb Study of Pirepemat Can Proceed as Planned After Positive Opinion from External Safety Committee

Price target decreased by 7.1% to kr56.63

IRLAB Therapeutics (STO:IRLAB A) Has Debt But No Earnings; Should You Worry?

IRLAB Therapeutics AB (publ) Announces CEO Changes, Effective from August 1, 2024

IRLAB Therapeutics AB (publ) Administers the First Dose in A Phase I Clinical Trial with the Drug Candidate Irl757

Price target increased by 8.0% to kr60.95

Consensus revenue estimates increase by 178%

Director recently bought kr260k worth of stock

IRLAB Has Received Approval from the Swedish Medical Products Agency to Conduct a Phase I Study of the Drug Candidate IRL757

New major risk - Financial position

IRLAB Therapeutics AB Completes End-Of-Phase 2 Meeting with the FDA on the Design of the Phase III Program for Mesdopetam

Consensus revenue estimates increase by 88%

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

IRLAB Therapeutics AB (publ) to Report Fiscal Year 2023 Results on Apr 29, 2024

IRLAB's Pioneering Phase IIb Study Withpirepemat - React-PD - Provides New Insights in Specific Parkinson's Patient Population and Enables a Data Driven Prediction of Study Timelines

Here's Why We're Watching IRLAB Therapeutics' (STO:IRLAB A) Cash Burn Situation

IRLAB Therapeutics AB's Drug Candidate IRL757 Completes all Preclinical Studies and Development Work Necessary to Start Phase I

IRLAB Therapeutics AB (publ) Submits Request for an End-Of-Phase 2 Meeting with the FDA for the Phase III-Ready Mesdopetam Program

IRLAB Therapeutics AB Receives Additional Patent for Drug Candidate Pirepemat That Expands its Patent Protection

New minor risk - Profitability

IRLAB Therapeutics AB (publ) Announces Appointment to its Nomination Committee

Third quarter 2023 earnings released

IRLAB Therapeutics AB (publ) to Report Q1, 2024 Results on May 08, 2024

Here's Why IRLAB Therapeutics (STO:IRLAB A) Must Use Its Cash Wisely

Price target increased by 83% to kr59.05

Second quarter 2023 earnings released

IRLAB Secures Full Ownership of the Mesdopetam Project and Continues Product Development

Less than half of directors are independent

IRLAB Therapeutics AB (publ) Elects Christer Nordstedt, Daniel Johnsson and Veronica Wallin as Board Members

IRLAB Therapeutics AB Announces That All Participating Study Sites in the Phase IIb Study of Pirepemat (IRL752) Are Activated and Recruiting Patients

IRLAB Therapeutics AB (publ) to Report Q3, 2023 Results on Oct 25, 2023

We Think IRLAB Therapeutics (STO:IRLAB A) Needs To Drive Business Growth Carefully

IRLAB Therapeutics Updates on Portfolio Development Milestones

IRLAB Therapeutics Announces Top-Line Results from Phase IIb Trial of Mesdopetam (IRL790) in Parkinson’s Disease

IRLAB Therapeutics AB Nominates IRL1117 as Drug Candidate from the P003 Project to Develop a Novel Treatment for Parkinson's Disease

IRLAB Therapeutics AB Reports Last Patient Last Visit (“Lplv”) Achieved in Phase Iib Clinical Study of Mesdopetam in Pd-Lids with Top-Line Results Anticipated Mid-January 2023

IRLAB Therapeutics (STO:IRLAB A) Is In A Good Position To Deliver On Growth Plans

IRLAB Therapeutics AB (publ) to Report Q1, 2023 Results on May 10, 2023

IRLAB Therapeutics AB Announces New Preclinical Data Indicating Phase IIb Drug Candidate Mesdopetam's Powerful Efficacy in Parkinson's Psychosis and PD-LIDs

IRLAB Therapeutics AB (publ) Appoints Nomination Committee Ahead of Annual General Meeting 2023

IRLAB Completes Recruitment in Phase IIb Study of Mesdopetam (IRL790) in Patients with Parkinson's Levodopa-Induced Dyskinesias

Consensus forecasts updated

IRLAB's Partner Ipsen Initiates Clinical Studies in Line with Mesdopetam's Development Plan

IRLAB's Partner Ipsen Initiates Clinical Studies in Line with Mesdopetam's Development Plan

Consensus forecasts updated

Irlab Therapeutics AB (Publ) Expands Phase IIb/III Pd-Lids Study with Mesdopetam to Support Phase Iii Program and Expects Completion of Enrollment During the Summer

IRLAB Therapeutics AB (publ) Appoints Richard Godfrey as CEO, Effective from 1 July 2022

Chief Financial Officer recently bought kr407k worth of stock

We Like IRLAB Therapeutics' (STO:IRLAB A) Earnings For More Than Just Statutory Profit

IRLAB Therapeutics AB (publ) Approves Board Appointments

Price target increased to kr69.50

Insufficient new directors

Insufficient new directors

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improved over the past week

Independent Vice Chairman of the Board recently bought kr330k worth of stock

IRLAB Therapeutics AB (publ) to Report Fiscal Year 2021 Results on Apr 08, 2022

Independent Chairman recently bought kr74k worth of stock

Irlab Obtains Regulatory Approval to Conduct Phase IIb Study with Pirepemat

Independent Director recently bought kr112k worth of stock

We're Interested To See How IRLAB Therapeutics (STO:IRLAB A) Uses Its Cash Hoard To Grow

Chief Medical Officer recently sold kr1.8m worth of stock